Posted by Michael Wonder on 03 Aug 2021
Mustang Bio receives European Medicines Agency PRIME designation for MB-107 to treat X-linked severe combined immunodeficiency in newly diagnosed infants
2 August 2021 - Mustang Bio today announced that the EMA has granted Priority Medicines designation to MB-107, its lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency in newly diagnosed infants, also known as bubble boy disease.
In addition to PRIME designation, the EMA granted Advanced Therapy Medicinal Product classification to MB-107 in April 2020 and orphan drug designation in November 2020.
